Skip to main content
. 2023 Nov 10;7(24):7554–7563. doi: 10.1182/bloodadvances.2023011181

Figure 4.

Figure 4.

OS of patients with MDS/MPN with neutrophilia in the Netherlands, from 2014 to 2019. The panels show the OS of patients with MDS/MPN with neutrophilia diagnosed during 2014 to 2019 according to the presence of (A) cytogenetic abnormalities, (B) epigenetic mutations, (C) signaling mutations, and (D) SRSF2 mutations and (E) the number of molecular mutations. The median OS and the 1-, 5-, and 10-year OS according to the characteristics shown in panels A-E are presented in supplemental Table 2.